RRx-001
- Generic Name
- RRx-001
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C5H6BrN3O5
- CAS Number
- 925206-65-1
- Unique Ingredient Identifier
- 7RPW6SU9SC
- Background
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
- Associated Conditions
- -
- Associated Therapies
- -
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 216
- Registration Number
- NCT05966194
- Locations
- 🇺🇸
Willis Knighton Cancer Center, Shreveport, Louisiana, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04525014
- Locations
- 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers
- Conditions
- Interventions
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03515538
- Locations
- 🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸John Wayne Cancer Institute @ Providence St. John's Health Center, Santa Monica, California, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
- Conditions
- Interventions
- First Posted Date
- 2016-06-15
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02801097
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of California, Davis, Sacramento, California, United States
A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02518958
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT02489903
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Baptist Health, Lexington, Kentucky, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02452970
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT02096341
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT02096354
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸Kaiser Permanete, Honolulu, Hawaii, United States
🇺🇸Stanford University, Stanford, California, United States
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01359982
- Locations
- 🇺🇸
Moores University of California San Diego Cancer Center, La Jolla, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.